Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Bristol Myers Squibb Company (NYSE:BMY) have been assigned an average recommendation of “Moderate Buy” from the twenty-five analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $67.06.

A number of equities analysts have weighed in on BMY shares. Citigroup reiterated a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Royal Bank Of Canada upped their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Bank of America cut their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $61.54 on Friday. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The stock’s fifty day moving average price is $64.44 and its two-hundred day moving average price is $60.15. The firm has a market cap of $125.71 billion, a PE ratio of 13.56, a PEG ratio of 0.30 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the company earned $1.46 EPS. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts forecast that Bristol Myers Squibb will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb selected Onco360 as a restricted specialty pharmacy for ZENBEXUS (iberdomide), enabling specialty dispensing and clinical support as the newly approved multiple myeloma treatment begins its commercial rollout. The launch could provide a new revenue stream in an underserved patient population. Bristol Myers Squibb Adds Restricted Pharmacy Path for New Myeloma Drug
• Positive Sentiment: Recent traction from newer medicines is helping offset declines from mature products, improving BMY’s revenue mix and supporting the investment case that its growth portfolio can soften upcoming patent losses. Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
• Positive Sentiment: Completion of a Phase 1 lung-cancer combination study adds incremental support to Bristol Myers Squibb’s immuno-oncology pipeline, though the early-stage update does not yet establish clinical or commercial success. BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline
• Positive Sentiment: Zacks added BMY to its Rank #1 Strong Buy list and its Strong Buy income-stock list, potentially improving sentiment among momentum and dividend-focused investors. New Strong Buy Stocks for September 24th
• Neutral Sentiment: Investment coverage highlights BMY’s specialized drug portfolio, strong free cash flow and generous dividend, but also notes the company’s exposure to patent expirations and the need for its pipeline to deliver the next phase of growth. Bristol Myers Squibb vs. Pfizer

Insider Transactions at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC increased its stake in shares of Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after purchasing an additional 368,193 shares in the last quarter. Callan Family Office LLC purchased a new position in Bristol Myers Squibb during the second quarter valued at $3,575,000. BlackRock Inc. grew its holdings in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. Asset One Wealth Management LLC bought a new stake in Bristol Myers Squibb during the fourth quarter valued at about $4,075,000. Finally, Motley Fool Asset Management LLC increased its position in Bristol Myers Squibb by 30.4% in the fourth quarter. Motley Fool Asset Management LLC now owns 216,468 shares of the biopharmaceutical company’s stock worth $11,676,000 after buying an additional 50,403 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.